Our expertise spans the full range of life sciences products. We advise on i.a. medicinal products, medical devices, in vitro diagnostics (IVDs), food and food supplements, biocidal products, and substances of human origin (SoHo). With a deep understanding of sector-specific legislation and regulatory frameworks, Alliance lawyers provide tailored solutions that support innovation while maintaining strict compliance with European and national laws.
Thanks to a shared focus on life sciences, the Alliance offers clients access to a network of professionals with both local insight and international reach. This enables us to provide coordinated advice across jurisdictions, assisting companies in navigating the diverse legal landscapes within Europe. Our approach combines practical industry knowledge with legal excellence, helping clients to anticipate risks and achieve their business objectives.
Whether you are developing a groundbreaking therapy, placing a new device on the market, addressing regulatory or marketing challenges in food or biocidal products, the Alliance of the European Life Sciences Law Firm stands ready to support you. Our members are committed to delivering clear, pragmatic guidance that empowers companies to innovate responsibly and grow with confidence in the dynamic life sciences environment.
The regulatory framework for life sciences in the European Union is one of the most comprehensive in the world, reflecting the critical importance of safeguarding patient safety, public health, and consumer protection. Medicinal products, medical devices, in vitro diagnostics (IVDs), food, biocidal products, and substances of human origin (SoHo) are all subject to detailed rules that govern their development, approval, and oversight. These frameworks ensure that innovation is balanced with rigorous standards of quality, efficacy, and safety.
For medicinal products, EU and national laws set strict requirements for clinical trials, marketing authorisations, pharmacovigilance, and manufacturing practices. Medical devices and IVDs are regulated through dedicated regulations that impose conformity assessments, post-market surveillance, and continuous performance monitoring. In the area of food and food supplements, EU law governs labelling, safety assessments, and health claims, while biocidal products must undergo authorisation procedures to verify their safety for humans and the environment. For SoHo, legislation addresses donation, testing, processing, and distribution, reflecting both ethical and public health considerations.
These legal frameworks extend across the entire product lifecycle. They address not only the initial development and research but also production, distribution, marketing, and ongoing market surveillance. Companies must comply with obligations ranging from good manufacturing practices to transparent interactions with healthcare professionals, and from ensuring truthful promotional activities to maintaining traceability and recall mechanisms.
At the same time, the regulatory environment gives rise to complex legal challenges. Questions often arise in borderline areas – such as e.g. whether certain nutritional products should be classified as food or as medicinal products, or how non-interventional studies in medical devices should be conducted and assessed under the law. Further difficulties concern i.a. compliance with rules on interactions with healthcare professionals, for example ensuring that compensation for services provided by doctors does not create conflicts of interest when their prescribing decisions involve products reimbursed from public funds. These challenges illustrate the need for precise legal expertise to navigate the intersection of law, science, and ethics in the life sciences sector.
